Literature DB >> 4062333

Treatment of urticaria pigmentosa with corticosteroids.

J Barton, R M Lavker, N M Schechter, G S Lazarus.   

Abstract

Based on a previous observation that the long-term application of potent topical corticosteroids under occlusion to normal skin resulted in the loss of mast cells, we investigated the effects of intralesional and topical steroids in urticaria pigmentosa (UP). Three patients with UP had lesions that were injected with triamcinolone acetonide. Four weeks after injection, all patients showed a loss of Darier's sign, and, by eight weeks after injection, there was a dramatic clearing of the plaques and a decrease in brown hyperpigmentation. By 12 weeks, mast cells were undetectable by light microscopy and transmission electron microscopy (TEM). The injection sites remained dramatically improved for as long as one year after treatment, and histamine content was reduced 95% in one patient 48 weeks after injection. In six patients, the topical application of 0.05% betamethasone dipropionate under occlusion to limited areas induced almost complete clearing of UP lesions. Lesions treated with an emollient under occlusion, as a control, demonstrated no change. After treatment, no mast cells were seen by light microscopy or TEM, and this persisted for at least 24 weeks. There was also a significant decrease in tissue histamine levels in the treated areas. The treated areas remained clinically improved for at least nine to 12 months. These data indicate that steroid therapy dramatically decreases the excess number of normal-appearing mast cells in UP as well as induces a prolonged resolution of UP lesions. Local corticosteroids thus are a useful therapeutic modality for UP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4062333

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

1.  Red-brown skin lesions and pruritus.

Authors:  J C Cather; M A Menter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-07

Review 2.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

3.  Bullous mastocytosis treated with oral betamethasone therapy.

Authors:  Kaushal K Verma; Radhakrishna Bhat; Manoj K Singh
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

4.  The effects of topical corticosteroids on delayed pressure urticaria.

Authors:  R J Barlow; D M Macdonald; A K Black; M W Greaves
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

5.  Mast cell density in psoriatic skin. The effect of PUVA and corticosteroid therapy.

Authors:  S Töyry; J Fräki; R Tammi
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

Review 6.  Mastocytosis.

Authors:  Melody C Carter; Dean D Metcalfe; Hirsh D Komarow
Journal:  Immunol Allergy Clin North Am       Date:  2013-10-07       Impact factor: 3.479

7.  Regulation of normal and neoplastic human mast cell development in mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

8.  Protective effects of doxepin cream on radiation dermatitis in breast cancer: A single arm double-blind randomized clinical trial.

Authors:  Laleh Shariati; Alireza Amouheidari; Hajar Naji Esfahani; Alireza Abed; Shaghayegh Haghjooy Javanmard; Ismail Laher; Ahmad Ghasemi; Golnaz Vaseghi
Journal:  Br J Clin Pharmacol       Date:  2020-02-25       Impact factor: 4.335

Review 9.  Pediatric Mastocytosis: Recognition and Management.

Authors:  Julie V Schaffer
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 7.403

Review 10.  Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.

Authors:  David González-de-Olano; Almudena Matito; Alberto Orfao; Luis Escribano
Journal:  F1000Res       Date:  2016-11-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.